Co-infections and antimicrobial use among hospitalized COVID-19 patients in Punjab, Pakistan: findings from a multicenter, point prevalence survey

References

• World Health Organization (WHO). Listings of WHO’s response to COVID-19. [Accessed on, 20 June, 2021.]. Available from: https://www.who.int/news/item/29-06-2020-covidtimeline
   Google Scholar
• Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27(4):520–531.
   Web of Science ®Google Scholar
• Beović B, Doušak M, Ferreira-Coimbra J, et al. Antibiotic use in patients with COVID-19: a ‘snapshot’Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75(11):3386–3390.
   PubMed Web of Science ®Google Scholar
• Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26(12):1622–1629.
   Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Moretto F, Sixt T, Devilliers H, et al. Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19? Inter J Infect Dis. 2021;105:256–260.
   PubMed Web of Science ®Google Scholar
• Hassan M, Biswas M, Al Jubayer A, et al. Use of antimicrobials among suspected COVID-19 patients at selected hospitals, bangladesh: findings from the first wave of COVID-19 pandemic. Antibiotics. 2021;10(6):738.
   Google Scholar
• Cheng LS, Chau SK, Tso EY, et al. Bacterial co-infections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster. Therapeutic Advances in Infectious Disease. 2020;7:2049936120978095.
   Google Scholar
• Townsend L, Hughes G, Kerr C, et al. Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection. JAC-Antimicrobial Resistance. 2020;2(3):dlaa071.
   Google Scholar
• Tan SH, Ng TM, Tay HL, et al. A point prevalence survey to assess antibiotic prescribing in patients hospitalized with confirmed and suspected coronavirus disease 2019 (COVID-19). J Glob Antimicrob Resist. 2021;24:45–47.
   PubMed Web of Science ®Google Scholar
• Ng TM, Tan SH, Heng ST, et al. Effects of coronavirus disease 2019 (COVID-19) pandemic on antimicrobial prevalence and prescribing in a tertiary hospital in Singapore. Antimicrob Resist Infect Control. 2021;10(1):1–8.
   PubMed Web of Science ®Google Scholar
• Godman B, Egwuenu A, Haque M, et al. Strategies to improve antimicrobial utilization with a special focus on developing countries. Life. 2021;11(6):528.
   PubMedGoogle Scholar
• Seaton RA, Gibbons CL, Cooper L, et al. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect. 2020;81(6):952–960.
   PubMed Web of Science ®Google Scholar
• Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PloS One. 2017;12(12):e0189621.
   PubMed Web of Science ®Google Scholar
• Hofer U. The cost of antimicrobial resistance. Nature Rev Microbiol. 2019;17(1):3.
   PubMedGoogle Scholar
• World Health Organization. Antimicrobial resistance. [Accessed on 04 July, 2021]. Accessed from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
   Google Scholar
• National Academies of Sciences E, Medicine, Health, Medicine D, Board on Global H, Forum on Microbial T. Understanding the economics of microbial threats: proceedings of a workshop. Washington (DC): National Academies Press (US). Copyright 2018 by the National Academy of Sciences. All rights reserved; 2018.
   Google Scholar
• Jung IY, Kim JJ, Lee SJ, et al. Antibiotic-related adverse drug reactions at a tertiary care hospital in South Korea. Biomed Res Int. 2017;2017:1–7.
   Web of Science ®Google Scholar
• Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903.
   PubMed Web of Science ®Google Scholar
• Mustafa ZU, Salman M, Raza MH, et al. Ceftriaxone induced cardiopulmonary arrest: a fatal case report. Archives of Pharmacy Practice. 2021;12(1):115–117.
   Google Scholar
• World Health Organization (WHO). Global action plan on antimicrobial resistance. [Accessed on 04 July, 2021]. Accessed from URL: https://www.who.int/publications/i/item/9789241509763
   Google Scholar
• World Health Organization (WHO). (2018). Essential medicines and health products. WHO Methodology for Point Prevalence Survey on Antibiotic Use in Hospitals. [Cited 2021 Jul 04]. Available from URL: https://www.who.int/medicines/access/antimicrobial_resistance/WHO-EMP-IAU-2018_01/en/
   Google Scholar
• Saleem Z, Hassali MA, Hashmi FK, et al. A repeated point prevalence survey of antimicrobial use in specialized cancer care hospital of Pakistan: findings and implications. Hosp Pract. 2019;47(3):149–154.
   PubMedGoogle Scholar
• Saleem Z, Godman B, Hassali MA, et al. Point prevalence surveys of health-care-associated infections: a systematic review. Pathog Glob Health. 2019;113(4):191–205.
   PubMed Web of Science ®Google Scholar
• Saleem Z, Hassali MA, Godman B, et al. Point prevalence surveys of antimicrobial use: a systematic review and the implications. Expert Rev Anti Infect Ther. 2020;18(9):897–910.
   PubMed Web of Science ®Google Scholar
• Saleem Z, Hassali MA, Versporten A, et al. A multicenter point prevalence survey of antibiotic use in Punjab, Pakistan: findings and implications. Expert Rev Anti Infect Ther. 2019;17(4):285–293.
   PubMed Web of Science ®Google Scholar
• Mustafa ZU, Salman M, Yasir M, et al. Antibiotic consumption among hospitalized neonates and children in Punjab Province, Pakistan. Expert Rev Anti Infect Ther. 2021; 1–9. 10.1080/14787210.2021.1986388
   Web of Science ®Google Scholar
• Bilal H, Khan MN, Rehman T, et al. Antibiotic resistance in Pakistan: a systematic review of past decade. BMC Infect Dis. 2021;21(1):1–9.
   PubMed Web of Science ®Google Scholar
• Sriram A, Kalanxhi E, Kapoor G, et al. State of the world’s antibiotics 2021: a global analysis of antimicrobial resistance and its drivers. Center for Disease Dynamics, Economics & Policy: Washington DC. Cited 2021 Jul 04 Available at URLhttps://cddep.org/wp-content/uploads/2021/02/The-State-of-the-Worlds-Antibiotics-in-2021.pdf
   Google Scholar
• Mustafa ZU, Salman M, Aldeyab M, et al. Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. SN Compreh Clin Med. 2021;(3)1–5.
   Google Scholar
• Rana MS, Usman M, Salman M, et al. Potential impact of COVID-19 pandemic on escalating antimicrobial resistance in Pakistan. J Infect. 2021;83(3):e12–3.
   PubMed Web of Science ®Google Scholar
• Saleem Z, Hassali MA, Hashmi FK. Pakistan’s national action plan for antimicrobial resistance: translating ideas into reality. Lancet Infect Dis. 2018;18(10):1066–1067.
   PubMed Web of Science ®Google Scholar
• Saleem Z, Godman B, Azhar F, et al. Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a scoping review and the implications. Expert Rev Anti Infect Ther. 2021;1–23.
   PubMed Web of Science ®Google Scholar
• Khan MS, Durrance-Bagale A, Mateus A, et al. What are the barriers to implementing national antimicrobial resistance action plans? A novel mixed-methods policy analysis in Pakistan. Health Policy Plan. 2020;35(8):973–982.
   PubMed Web of Science ®Google Scholar
• European Center for Disease Control (ECDC). Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals, 2012. [Cited 2021 Jul 04]. Available from http://ecdc.europa.eu/en/publications/Publications/PPS-HAI-antimicrobial-use-EU-acute-care-hospitals-V5-3.pdf
   Google Scholar
• Ministry Of National Health Services. Regulations and coordination, government of Pakistan. clinical management guidelines for COVID-19 infections. [Cited 2021 Jul 04]. Accessed from URL: https://covid.gov.pk/guidelines/pdf/20200402%20Clinical%20Management%20Guidelines%20for%20COVID-19%20infections_1201.pdf
   Google Scholar
• Hsia Y, Lee BR, Versporten A, et al. Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries. Lancet Glob Health. 2019;7(7):e861–71.
   PubMed Web of Science ®Google Scholar
• Sharland M, Gandra S, Huttner B, et al. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use—the new 2019 essential medicines list becomes a global antibiotic stewardship tool. Lancet Infect Dis. 2019;19(12):1278–1280.
   PubMed Web of Science ®Google Scholar
• Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021;2(8):e354–e365.
   PubMedGoogle Scholar
• Subramanya SH, Czyż DM, Acharya KP, et al. The potential impact of the COVID-19 pandemic on antimicrobial resistance and antibiotic stewardship. In: VirusDisease. 2021. p. 1–8.
   Google Scholar
• Getahun H, Smith I, Trivedi K, et al. Tackling antimicrobial resistance in the COVID-19 pandemic. Bull World Health Organ. 2020;98(7):442.
   PubMed Web of Science ®Google Scholar
• Majumder MA, Rahman S, Cohall D, et al. Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health. Infect Drug Resist. 2020;13:4713.
   PubMed Web of Science ®Google Scholar
• Molla MM, Yeasmin M, Islam MK, et al. Antibiotic prescribing patterns at COVID-19 dedicated wards in bangladesh: findings from a single center study. Infection Prevention in Practice. 2021;3(2):100134.
   Google Scholar
• Hassan M, Biswas M, Al Jubayer A. Use of antimicrobials among suspected COVID-19 patients at selected hospitals, Bangladesh: findings from the first wave of COVID-19 pandemic. Antibiotics. 2021;10(6):738.
   Google Scholar
• Pettit NN, Nguyen CT, Lew AK, et al. Reducing the use of empiric antibiotic therapy in COVID-19 on hospital admission. BMC Infect Dis. 2021;21(1):1–7.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Rossolini GM, Schultsz C, et al. Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance. In: Transactions of the royal society of tropical medicine and hygiene. 2021.
   Google Scholar
• Mustafa ZU, Salman M, Rao AZ, et al. Assessment of antibiotics use for children upper respiratory tract infections: a retrospective, cross-sectional study from Pakistan. Infect Dis (Auckl). 2020;52(7):473–478.
   PubMed Web of Science ®Google Scholar
• Mustafa ZU, Salman M, Aslam N, et al. Antibiotic use among hospitalized children with lower respiratory tract infections: a multicenter, retrospective study from Punjab, Pakistan. Expert Rev Anti Infect Ther. 2021; 1–6. 10.1080/14787210.2021.1935235
   Web of Science ®Google Scholar
• Saleem Z, Godman B, Azhar F, et al. Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a scoping review and the implications. Expert Rev Anti Infect Ther. 2021; 1–23. 10.1080/14787210.2021.1935238
   PubMed Web of Science ®Google Scholar
• Saleem Z, Hassali MA, Hashmi FK. Pakistan’s national action plan for antimicrobial resistance: translating ideas into reality. Lancet Infect Dis. 2018;18(10):1066–1067.
   PubMed Web of Science ®Google Scholar
• Vijay S, Bansal N, Rao BK, et al. Secondary infections in hospitalized COVID-19 patients: indian experience. Infect Drug Resist. 2021;14:1893.
   PubMed Web of Science ®Google Scholar
• Ng TM, Tan SH, Heng ST, et al. Effects of coronavirus disease 2019 (COVID-19) pandemic on antimicrobial prevalence and prescribing in a tertiary hospital in Singapore. Antimicrob Resist Infect Control. 2021;10(1):1–8.
   PubMed Web of Science ®Google Scholar